revumenib – Medxy AI

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib

By MedXY 03/29/2026

A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for specialized flow cytometry monitoring during menin inhibitor therapy.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Beyond Blast Counts: How Menin Inhibition Redefines AML Immunophenotypes and Survival

By MedXY 03/16/2026

This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor of long-term survival, necessitating new approaches to flow cytometry monitoring.

$Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML$

Hematology-Oncology Specialties

Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML

By MedXY 08/29/2025

The phase 2 AUGMENT-101 study demonstrates that revumenib, a selective menin inhibitor, induces meaningful remissions and enables stem cell transplantation in heavily pretreated, older patients with relapsed or refractory NPM1-mutated AML, addressing a critical unmet need.

Clinical Updates Hematology-Oncology news Specialties

Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

By MedXY 08/07/2025

A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.